Outset Medical

History

2020: Entry into the exchange

At the end of September, 2020 the equipment manufacturer for dialysis of Outset Medical went public and was estimated at $2.5 billion. After primary public placement of 10.3 million stocks Outset Medical attracted $277.9 million. Primary share price was $27, by September 18 the share price was $60.01. Sale of shares included the option of underwriters for purchase of 1.3 million additional actions at the price of $27 for an action.

The CEO of the company Leslie Trigg noted that the high interest of investors in Outset and the dialysis device Tablo was probably caused by a number of "structural changes for benefit of equipment manufacturing for dialysis" which occurred recently. Among them Trigg noted the state policy encouraging dialysis expansion at home, stimulation payments to the dialysis centers using new technologies and also potential benefits which dialysis provides at home during a pandemic.

The equipment manufacturer for dialysis of Outset Medical went public

Shortly before entry into the Outset exchange released the system of a hemodialysis held for use in conditions at home and also for treatment in the conditions of emergency aid in hospitals. Trigg noted that this first device in 15 years which was released in the USA for carrying out a hemodialysis in house conditions. According to Trigga, such situation is inadmissible in the conditions of the state support which "Improvement of health of kidneys in America" and the new criteria of a terminal renal failure requiring carrying out dialysis according to the insurance program Medicare Advantage provided the decree of the president on an initiative.

Trigg noted that his companies the last break were provided by COVID-19 pandemic along with rapid implementation of telemedicine.

These changes in the market happen right now, and they need to be used. It means to our company to appear in the right place in due time with necessary technologies.[1]

Notes